Evidence map›Paper›PMID 42038317›Full record

ArticleFrontiers in pharmacology2026

Biomimetic astragaloside-IV-loaded mesoporous silica nanoparticles for treatment of dilated cardiomyopathy.

Chenghua Wang, Lu Lv, Tao Long, Tiantian Xie, Junqing Qi, Huiwen Pan, Yifen Fang, Yangyong Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chenghua Wang *Department of Cardiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Lu Lv *Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Tao Long *Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Tiantian XieJiangsu Medical College, Yancheng, China.
Junqing QiDepartment of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Huiwen PanDepartment of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Yifen FangDepartment of Cardiology, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China.
Yangyong SunDepartment of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dilated cardiomyopathy (DCM) is currently the most prevalent form of cardiomyopathy; it poses a severe threat to human health and is characterized by poor prognosis and high mortality. In this study, we prepared macrophage-membrane-coated and astragaloside-IV-loaded mesoporous silica nanoparticles (AS@MSN/TA/MM) and assessed their therapeutic effects

Indexed as

astragaloside IVcardiac dysfunctiondilated cardiomyopathymacrophage membranemesoporous silica nanoparticles

Identifiers

PMID42038317
PMCPMC13102649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.